Pharma sector calls for drug prices to build in real-world value

The pharmaceutical industry wants future negotiations on drug pricing to include the extent to which drugs prevent costly hospital stays and details of other societal benefits they generate.

Aidan Lynch, general manager of GSK and president of the Irish Pharmaceutical Healthcare Association (IPHA), which represents the industry, said: “If we could look, not just at price in isolation, but at an end-to-end cost, such as bed days and reduced staff required – that ...